Atomoxetine reverses locomotor hyperactivity, impaired novel object recognition, and prepulse inhibition impairment in mice lacking pituitary adenylate cyclase-activating polypeptide

Y. Shibasaki, A. Hayata-Takano, K. Hazama, T. Nakazawa, N. Shintani, A. Kasai, K. Nagayasu, R. Hashimoto, M. Tanida, T. Katayama, S. Matsuzaki, K. Yamada, M. Taniike, Y. Onaka, Y. Ago, J. A. Waschek, K. Köves, D. Reglodi, A. Tamás, T. MatsudaA. Baba, H. Hashimoto

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Attention-deficit/hyperactivity disorder (ADHD) is a complex neurobehavioral disorder that is characterized by attention difficulties, impulsivity, and hyperactivity. A non-stimulant drug, atomoxetine (ATX), which is a selective noradrenaline reuptake inhibitor, is widely used for ADHD because it exhibits fewer adverse effects compared to conventional psychostimulants. However, little is known about the therapeutic mechanisms of ATX. ATX treatment significantly alleviated hyperactivity of pituitary adenylate cyclase-activating polypeptide (PACAP)-deficient (PACAP-/-) mice with C57BL/6J and 129S6/SvEvTac hybrid background. ATX also improved impaired novel object recognition memory and prepulse inhibition in PACAP-/- mice with CD1 background. The ATX-induced increases in extracellular noradrenaline and dopamine levels were significantly higher in the prefrontal cortex of PACAP-/- mice compared to wild-type mice with C57BL/6J and 129S6/SvEvTac hybrid background. These results suggest that ATX treatment-induced increases in central monoamine metabolism may be involved in the rescue of ADHD-related abnormalities in PACAP-/- mice. Our current study suggests that PACAP-/- mice are an ideal rodent model with predictive validity for the study of ADHD etiology and drug development. Additionally, the potential effects of differences in genetic background of PACAP-/- mice on behaviors are discussed.

Original languageEnglish
Pages (from-to)95-104
Number of pages10
JournalNeuroscience
Volume297
DOIs
Publication statusPublished - Jun 5 2015

Fingerprint

Pituitary Adenylate Cyclase-Activating Polypeptide
Attention Deficit Disorder with Hyperactivity
Inbred C57BL Mouse
Norepinephrine
Impulsive Behavior
Prefrontal Cortex
Pharmaceutical Preparations
Recognition (Psychology)
Atomoxetine Hydrochloride
Prepulse Inhibition
Rodentia
Dopamine
Therapeutics

Keywords

  • Atomoxetine (ATX)
  • Attention-deficit/hyperactivity disorder (ADHD)
  • Hyperactivity
  • Memory
  • Pituitary adenylate cyclase-activating polypeptide (PACAP)
  • Prepulse inhibition

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Atomoxetine reverses locomotor hyperactivity, impaired novel object recognition, and prepulse inhibition impairment in mice lacking pituitary adenylate cyclase-activating polypeptide. / Shibasaki, Y.; Hayata-Takano, A.; Hazama, K.; Nakazawa, T.; Shintani, N.; Kasai, A.; Nagayasu, K.; Hashimoto, R.; Tanida, M.; Katayama, T.; Matsuzaki, S.; Yamada, K.; Taniike, M.; Onaka, Y.; Ago, Y.; Waschek, J. A.; Köves, K.; Reglodi, D.; Tamás, A.; Matsuda, T.; Baba, A.; Hashimoto, H.

In: Neuroscience, Vol. 297, 05.06.2015, p. 95-104.

Research output: Contribution to journalArticle

Shibasaki, Y, Hayata-Takano, A, Hazama, K, Nakazawa, T, Shintani, N, Kasai, A, Nagayasu, K, Hashimoto, R, Tanida, M, Katayama, T, Matsuzaki, S, Yamada, K, Taniike, M, Onaka, Y, Ago, Y, Waschek, JA, Köves, K, Reglodi, D, Tamás, A, Matsuda, T, Baba, A & Hashimoto, H 2015, 'Atomoxetine reverses locomotor hyperactivity, impaired novel object recognition, and prepulse inhibition impairment in mice lacking pituitary adenylate cyclase-activating polypeptide', Neuroscience, vol. 297, pp. 95-104. https://doi.org/10.1016/j.neuroscience.2015.03.062
Shibasaki, Y. ; Hayata-Takano, A. ; Hazama, K. ; Nakazawa, T. ; Shintani, N. ; Kasai, A. ; Nagayasu, K. ; Hashimoto, R. ; Tanida, M. ; Katayama, T. ; Matsuzaki, S. ; Yamada, K. ; Taniike, M. ; Onaka, Y. ; Ago, Y. ; Waschek, J. A. ; Köves, K. ; Reglodi, D. ; Tamás, A. ; Matsuda, T. ; Baba, A. ; Hashimoto, H. / Atomoxetine reverses locomotor hyperactivity, impaired novel object recognition, and prepulse inhibition impairment in mice lacking pituitary adenylate cyclase-activating polypeptide. In: Neuroscience. 2015 ; Vol. 297. pp. 95-104.
@article{9aa3fd26217349a580844b0b07aa9d80,
title = "Atomoxetine reverses locomotor hyperactivity, impaired novel object recognition, and prepulse inhibition impairment in mice lacking pituitary adenylate cyclase-activating polypeptide",
abstract = "Attention-deficit/hyperactivity disorder (ADHD) is a complex neurobehavioral disorder that is characterized by attention difficulties, impulsivity, and hyperactivity. A non-stimulant drug, atomoxetine (ATX), which is a selective noradrenaline reuptake inhibitor, is widely used for ADHD because it exhibits fewer adverse effects compared to conventional psychostimulants. However, little is known about the therapeutic mechanisms of ATX. ATX treatment significantly alleviated hyperactivity of pituitary adenylate cyclase-activating polypeptide (PACAP)-deficient (PACAP-/-) mice with C57BL/6J and 129S6/SvEvTac hybrid background. ATX also improved impaired novel object recognition memory and prepulse inhibition in PACAP-/- mice with CD1 background. The ATX-induced increases in extracellular noradrenaline and dopamine levels were significantly higher in the prefrontal cortex of PACAP-/- mice compared to wild-type mice with C57BL/6J and 129S6/SvEvTac hybrid background. These results suggest that ATX treatment-induced increases in central monoamine metabolism may be involved in the rescue of ADHD-related abnormalities in PACAP-/- mice. Our current study suggests that PACAP-/- mice are an ideal rodent model with predictive validity for the study of ADHD etiology and drug development. Additionally, the potential effects of differences in genetic background of PACAP-/- mice on behaviors are discussed.",
keywords = "Atomoxetine (ATX), Attention-deficit/hyperactivity disorder (ADHD), Hyperactivity, Memory, Pituitary adenylate cyclase-activating polypeptide (PACAP), Prepulse inhibition",
author = "Y. Shibasaki and A. Hayata-Takano and K. Hazama and T. Nakazawa and N. Shintani and A. Kasai and K. Nagayasu and R. Hashimoto and M. Tanida and T. Katayama and S. Matsuzaki and K. Yamada and M. Taniike and Y. Onaka and Y. Ago and Waschek, {J. A.} and K. K{\"o}ves and D. Reglodi and A. Tam{\'a}s and T. Matsuda and A. Baba and H. Hashimoto",
year = "2015",
month = "6",
day = "5",
doi = "10.1016/j.neuroscience.2015.03.062",
language = "English",
volume = "297",
pages = "95--104",
journal = "Neuroscience",
issn = "0306-4522",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Atomoxetine reverses locomotor hyperactivity, impaired novel object recognition, and prepulse inhibition impairment in mice lacking pituitary adenylate cyclase-activating polypeptide

AU - Shibasaki, Y.

AU - Hayata-Takano, A.

AU - Hazama, K.

AU - Nakazawa, T.

AU - Shintani, N.

AU - Kasai, A.

AU - Nagayasu, K.

AU - Hashimoto, R.

AU - Tanida, M.

AU - Katayama, T.

AU - Matsuzaki, S.

AU - Yamada, K.

AU - Taniike, M.

AU - Onaka, Y.

AU - Ago, Y.

AU - Waschek, J. A.

AU - Köves, K.

AU - Reglodi, D.

AU - Tamás, A.

AU - Matsuda, T.

AU - Baba, A.

AU - Hashimoto, H.

PY - 2015/6/5

Y1 - 2015/6/5

N2 - Attention-deficit/hyperactivity disorder (ADHD) is a complex neurobehavioral disorder that is characterized by attention difficulties, impulsivity, and hyperactivity. A non-stimulant drug, atomoxetine (ATX), which is a selective noradrenaline reuptake inhibitor, is widely used for ADHD because it exhibits fewer adverse effects compared to conventional psychostimulants. However, little is known about the therapeutic mechanisms of ATX. ATX treatment significantly alleviated hyperactivity of pituitary adenylate cyclase-activating polypeptide (PACAP)-deficient (PACAP-/-) mice with C57BL/6J and 129S6/SvEvTac hybrid background. ATX also improved impaired novel object recognition memory and prepulse inhibition in PACAP-/- mice with CD1 background. The ATX-induced increases in extracellular noradrenaline and dopamine levels were significantly higher in the prefrontal cortex of PACAP-/- mice compared to wild-type mice with C57BL/6J and 129S6/SvEvTac hybrid background. These results suggest that ATX treatment-induced increases in central monoamine metabolism may be involved in the rescue of ADHD-related abnormalities in PACAP-/- mice. Our current study suggests that PACAP-/- mice are an ideal rodent model with predictive validity for the study of ADHD etiology and drug development. Additionally, the potential effects of differences in genetic background of PACAP-/- mice on behaviors are discussed.

AB - Attention-deficit/hyperactivity disorder (ADHD) is a complex neurobehavioral disorder that is characterized by attention difficulties, impulsivity, and hyperactivity. A non-stimulant drug, atomoxetine (ATX), which is a selective noradrenaline reuptake inhibitor, is widely used for ADHD because it exhibits fewer adverse effects compared to conventional psychostimulants. However, little is known about the therapeutic mechanisms of ATX. ATX treatment significantly alleviated hyperactivity of pituitary adenylate cyclase-activating polypeptide (PACAP)-deficient (PACAP-/-) mice with C57BL/6J and 129S6/SvEvTac hybrid background. ATX also improved impaired novel object recognition memory and prepulse inhibition in PACAP-/- mice with CD1 background. The ATX-induced increases in extracellular noradrenaline and dopamine levels were significantly higher in the prefrontal cortex of PACAP-/- mice compared to wild-type mice with C57BL/6J and 129S6/SvEvTac hybrid background. These results suggest that ATX treatment-induced increases in central monoamine metabolism may be involved in the rescue of ADHD-related abnormalities in PACAP-/- mice. Our current study suggests that PACAP-/- mice are an ideal rodent model with predictive validity for the study of ADHD etiology and drug development. Additionally, the potential effects of differences in genetic background of PACAP-/- mice on behaviors are discussed.

KW - Atomoxetine (ATX)

KW - Attention-deficit/hyperactivity disorder (ADHD)

KW - Hyperactivity

KW - Memory

KW - Pituitary adenylate cyclase-activating polypeptide (PACAP)

KW - Prepulse inhibition

UR - http://www.scopus.com/inward/record.url?scp=84927611383&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84927611383&partnerID=8YFLogxK

U2 - 10.1016/j.neuroscience.2015.03.062

DO - 10.1016/j.neuroscience.2015.03.062

M3 - Article

C2 - 25841321

AN - SCOPUS:84927611383

VL - 297

SP - 95

EP - 104

JO - Neuroscience

JF - Neuroscience

SN - 0306-4522

ER -